MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$25,646,892
Free Cash flow
-$6,010,177
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Accounts payable and accrued lia...
Change in operating lease right-...
Others
Negative Cash Flow Breakdown
Net loss
Proceeds from exercise of warran...
Change in fair value of warrants
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-6,930,652
-5,653,946
-5,295,221
-4,443,876
Depreciation and amortization
35,524
-110,018
49,461
164,136
Stock-based compensation expense
428,306
451,869
567,788
567,788
Change in operating lease right-of-use asset
49,450
-3,246
20,169
56,033
Change in fair value of warrants
-132,000
-77,000
-297,833
-294,276
Prepaid expenses and other current assets
-42,593
-245,498
-224,977
-509,170
Lease liability
2,747
-
-22,343
-21,580
Accounts payable and accrued liabilities
493,855
301,278
408,866
-664,031
Cash used in operating activities
-6,010,177
-4,845,565
-4,344,136
-4,275,121
Purchases of property, plant & equipment
0
3,378
5,880
-
Cash used in investing activities
0
-3,378
-5,880
-
Proceeds from exercise of warrants and new warrants, net of issuance costs
-
-
7,243,140
3
Proceeds from exercise of warrants, net of issuance costs (note 2)
-2,251,377
-
-
0
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs (note 2)
31,657,066
-
0
5,788,380
Cash provided by financing activities
31,657,069
-
4,991,760
5,788,383
Net (decrease) increase in cash and cash equivalents
25,646,892
-4,848,943
641,744
1,513,262
Cash and cash equivalents at beginning of period
8,347,090
13,196,033
12,554,289
23,288,607
Cash and cash equivalents at end of period
33,993,982
8,347,090
13,196,033
12,554,289
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$31,657,066
something is missing
$2,251,380
Cash provided by
financing activities
$31,657,069
(1306.12%↑ Y/Y)
Canceled cashflow
$2,251,377
Net (decrease)
increase in cash and cash...
$25,646,892
(309.40%↑ Y/Y)
Canceled cashflow
$6,010,177
Proceeds from exercise of
warrants, net of issuance...
-$2,251,377
(-200.00%↓ Y/Y)
Accounts payable and
accrued liabilities
$493,855
(116.99%↑ Y/Y)
Stock-based compensation
expense
$428,306
(-62.03%↓ Y/Y)
Change in operating
lease right-of-use...
$49,450
(35.01%↑ Y/Y)
Prepaid expenses and
other current assets
-$42,593
(-106.93%↓ Y/Y)
Depreciation and
amortization
$35,524
(-68.24%↓ Y/Y)
Lease liability
$2,747
(106.78%↑ Y/Y)
Cash used in
operating activities
-$6,010,177
(58.55%↑ Y/Y)
Canceled cashflow
$1,052,475
Net loss
-$6,930,652
(42.49%↑ Y/Y)
Change in fair value of
warrants
-$132,000
(18.32%↑ Y/Y)
Buy us a coffee
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)